Brokers upbeat on Eiger Biopharmaceuticals Inc despite economic uncertainty

The Eiger Biopharmaceuticals Inc (NMQ:EIGR) share price has risen by 3.98% over the past month and it’s currently trading at 10.98. For investors considering whether to buy, hold or sell the stock, the question now is whether this price run will continue.

According to the company’s analysts, there are certainly reasons to think it will continue to perform well in the year ahead. In terms of trading recommendations, Eiger Biopharmaceuticals Inc currently has:

• 6 Buy recommendations

• 0 Hold recommendations

• 0 Sell recommendations

This suggests that analysts are generally positive about the outlook.

GET MORE DATA-DRIVEN INSIGHTS INTO NMQ:EIGR »

Researching beyond broker forecasts

At its current price of 10.98, shares in Eiger Biopharmaceuticals Inc are trading at a discount of -30.6% to its 52 week high price. The 1-year performance of the shares has been 8.18%.

While analyst forecasts can be a useful guide to what City 'experts' think about a stock's near term future, they can be unreliable. To get a better idea about the strengths and weaknesses of Eiger Biopharmaceuticals Inc it's worth doing some investigation yourself.

There are all sorts of factors that could affect Eiger Biopharmaceuticals Inc's share price this year – we simplify them into easy to understand scores with our Stockopedia StockReport. Click here to take a look at the StockReport for Eiger Biopharmaceuticals Inc – you might discover some surprising things you didn’t know.